Literature DB >> 50129

Binding of bleomycin to DNA in bleomycin-sensitive and -resistant rat ascites hepatoma cells.

M Miyaki, T Ono, S Hori, H Umezawa.   

Abstract

The 14C activity of [14C]bleomycin bound to DNA in bleomycin-sensitive rat ascites hepatoma cells (AH-66) was 8.7 times higher than in resistant cells (AH-66F) when the cells were incubated with [14C]bleomycin. The difference in permeability to bleomycin was not significant; uptake of [14C]bleomycin by the sensitive cells was only 1.2 times larger than that by the resistant cells, and the radioactivity incorporated into the nuclei of sensitive cells was only 1.3-fold greater. The bleomycin-inactivating enzyme level in the resistant cells was 3.5 times higher than in the sensitive cells, indicating that the antibiotic incorporated into the resistent cells was reduced in DNA-binding activity to a large extent. The level of protein-free thiol compound in the sensitive cells was 1.8-fold higher than in the resistant cells, suggesting a possible enhancement of bleomycin action by intracellular thiol compound as is found in vitro. These factors probably affect the DNA strand scission and the sensitivity of cells to this antibiotic. Binding of [14C]bleomycin to DNA in vitro was studied in the presence and the absence of dithiothreitol. A large portion of the radioactivity bound in the presence of dithiothreitol was unstable to acid, but the acid-resistant binding was also enhanced by this thiol compound.

Entities:  

Mesh:

Substances:

Year:  1975        PMID: 50129

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  7 in total

Review 1.  Antineoplastic drugs: clinical pharmacology and therapeutic use.

Authors:  R A Bender; L A Zwelling; J H Doroshow; G Y Locker; K R Hande; D S Murinson; M Cohen; C E Myers; B A Chabner
Journal:  Drugs       Date:  1978-07       Impact factor: 9.546

2.  High-performance liquid chromatography assay of bleomycin in human plasma and rat hepatocytes in culture.

Authors:  R Mahdadi; A Kenani; N Pommery; J Pommery; J P Hénichart; M Lhermitte
Journal:  Cancer Chemother Pharmacol       Date:  1991       Impact factor: 3.333

Review 3.  Chemotherapeutic drug resistance in the management of head and neck cancer.

Authors:  H Bier
Journal:  Eur Arch Otorhinolaryngol       Date:  1993       Impact factor: 2.503

4.  Isolation and characterization of Saccharomyces cerevisiae mutants with enhanced resistance to the anticancer drug bleomycin.

Authors:  Mustapha Aouida; Omar Tounekti; Anick Leduc; Omrane Belhadj; Lluis Mir; Dindial Ramotar
Journal:  Curr Genet       Date:  2004-03-09       Impact factor: 3.886

Review 5.  Protective mechanisms against the antitumor agent bleomycin: lessons from Saccharomyces cerevisiae.

Authors:  Dindial Ramotar; Huijie Wang
Journal:  Curr Genet       Date:  2003-04-16       Impact factor: 3.886

6.  The human carnitine transporter SLC22A16 mediates high affinity uptake of the anticancer polyamine analogue bleomycin-A5.

Authors:  Mustapha Aouida; Richard Poulin; Dindial Ramotar
Journal:  J Biol Chem       Date:  2009-12-25       Impact factor: 5.157

7.  Further characterization of bleomycin-resistant HeLa cells and analysis of resistance mechanism.

Authors:  M Urade; M Sugi; T Matsuya
Journal:  Jpn J Cancer Res       Date:  1988-04
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.